🧠 Alzheimer's Disease-Modifying Therapy Cost-Access Simulator

Annual Cost of Disease-Modifying Alzheimer's Therapy

Placeholder: annual list price of anti-amyloid therapy overview.

• $26.5k: List price/year (Placeholder cost figure)
• Biweekly: Infusion frequency (Placeholder dosing note)
• +$10k+: Add-on costs (Placeholder monitoring add-on)
• Varies: Medicare share (Placeholder coverage note)

Drug pricing placeholder

Placeholder: list price structure and payer negotiation summary. Placeholder: cost comparison across approved therapies.

Insurance Coverage Determination and Prior Authorization

Placeholder: how payers determine reimbursement eligibility.

• High: Prior auth rate (Placeholder approval friction)
• Conditional: Medicare coverage (Placeholder CED note)
• Variable: Private payer gap (Placeholder variance note)
• Moderate: Appeal success (Placeholder appeals figure)

Coverage gate placeholder

Placeholder: eligibility criteria and registry requirements. Placeholder: denial and appeal pathway summary.

PET/MRI Monitoring Cost Burden Over Treatment Course

Placeholder: imaging surveillance requirements and cost stacking.

• 4-5: MRI scans/year (Placeholder ARIA monitoring)
• $5k+: PET scan cost (Placeholder amyloid PET cost)
• Significant: Out-of-pocket add (Placeholder burden note)
• Rural gap: Access disparity (Placeholder imaging access)

Monitoring burden placeholder

Placeholder: required scan schedule and safety monitoring. Placeholder: cumulative cost of surveillance imaging.

Infusion Center Access Barriers and Geographic Distance

Placeholder: distance and capacity limits on infusion access.

• Sparse: Rural centers (Placeholder facility density)
• 50+ mi: Avg travel distance (Placeholder distance figure)
• High: Capacity constraint (Placeholder wait time note)
• Substantial: Transport burden (Placeholder caregiver burden)

Access barrier placeholder

Placeholder: infusion center distribution and travel burden. Placeholder: caregiver time and transport cost impact.

Health Equity Access Gaps Across Populations

Placeholder: compounded disparities in therapy access by group.

• Low: Underserved uptake (Placeholder equity gap figure)
• Longer: Diagnostic delay (Placeholder diagnosis disparity)
• Limited: Trial representation (Placeholder trial diversity note)
• Compounding: Combined barrier effect (Placeholder cumulative effect)

Equity gap placeholder

Placeholder: cost, coverage, and access barriers compound inequitably. Placeholder: policy considerations for narrowing access gaps.

Placeholder: key equity insight summarizing combined barrier impact.